Sirolimus is a biochemical, functional form of rapamycin that disrupts the molecular interaction between mTOR and Raptor by targeting mTORC1 and is approved for the treatment of TSC manifestations, including SEGA. This evidence concerns the gene MTOR and tuberous sclerosis.